Abeona Therapeutics Inc

ABEONASDAQ · USD
2.60USD+0.18 (+7.44%)
322

Abeona Therapeutics Inc (ABEO) Historical Volatility

ABEO's 30 day historical volatility is 153.06%, in the 100th percentile of readings over the past year. This is a high percentile, meaning Abeona Therapeutics Inc shares have swung far more than usual. ABEO's 30 day implied volatility sits at 16,364.20%, with an IV Rank of 99.60%, leaving IV 16,211.14 points above historical volatility. This means options are pricing in more movement than the stock has actually delivered, as of Nov 13, 2026.

Read more

Tracking ABEO historical volatility helps you see how much Abeona Therapeutics Inc's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, ABEO's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor ABEO 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.

Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. ABEO's 30 day historical volatility, or ABEO HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing ABEO's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs.

Historical Volatility

HV Percentile
100thHV Percentile
High

Historical movement is elevated versus the past year. The stock has been unusually active.

Historical Volatility (30d)153.06%

HV Percentile100th

Implied Volatility (30d)16364.20%

IV Rank99.60%

IV Minus HV+16,211.14%

As of Nov 13, 2026

IV vs HV
Implied Volatility (IV) vs Historical Volatility (HV) over the past month.

As of Nov 13, 2026

IV - HV Difference
Difference between IV and HV over time. Positive values indicate IV > HV.

As of Nov 13, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →